Bausch Health Companies (NYSE:BHC) PT Set at $28.00 by Barclays
Barclays set a $28.00 target price on Bausch Health Companies (NYSE:BHC) in a research report sent to investors on Monday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock.
Other research analysts have also recently issued research reports about the company. Mizuho set a $45.00 target price on Bausch Health Companies and gave the company a buy rating in a research note on Thursday, June 20th. SunTrust Banks began coverage on Zoetis in a research note on Tuesday, March 19th. They issued a hold rating and a $100.00 price objective on the stock. ValuEngine cut Virtu Financial from a hold rating to a sell rating in a research note on Tuesday, June 18th. Cantor Fitzgerald set a $32.00 price objective on Bausch Health Companies and gave the stock a buy rating in a research note on Friday, May 31st. Finally, Wells Fargo & Co set a $9.00 price objective on Bausch Health Companies and gave the stock a sell rating in a research note on Friday, May 17th. Three analysts have rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the company. The company currently has an average rating of Hold and an average target price of $27.65.
BHC opened at $23.87 on Monday. The company has a market capitalization of $8.77 billion, a PE ratio of 5.99, a price-to-earnings-growth ratio of 0.56 and a beta of 0.78. The company’s 50 day simple moving average is $23.17. Bausch Health Companies has a one year low of $17.20 and a one year high of $28.45. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08.
A number of institutional investors have recently bought and sold shares of the business. Comerica Bank boosted its holdings in shares of Bausch Health Companies by 8.2% in the 4th quarter. Comerica Bank now owns 21,909 shares of the company’s stock valued at $529,000 after buying an additional 1,664 shares during the last quarter. LPL Financial LLC lifted its holdings in Bausch Health Companies by 7.0% during the 4th quarter. LPL Financial LLC now owns 23,121 shares of the company’s stock valued at $427,000 after purchasing an additional 1,514 shares during the last quarter. Aviva PLC lifted its holdings in Bausch Health Companies by 56.3% during the 4th quarter. Aviva PLC now owns 258,936 shares of the company’s stock valued at $4,796,000 after purchasing an additional 93,255 shares during the last quarter. Bessemer Group Inc. acquired a new stake in Bausch Health Companies during the 4th quarter valued at $33,000. Finally, Commonwealth Bank of Australia lifted its holdings in Bausch Health Companies by 9.5% during the 4th quarter. Commonwealth Bank of Australia now owns 133,058 shares of the company’s stock valued at $2,459,000 after purchasing an additional 11,545 shares during the last quarter. Institutional investors own 53.67% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.